PROJECT OBJECTIVE
The main objective of the project is to identify, through repurposing studies, well-known molecules with an optimal safety profile and with market approval for different indications, which have as a new molecular target the endogenous enzymes responsible for the degradation of endocannabinoids: monoacylglycerol-lipase and fatty acid amide hydrolase. Inhibition of these enzymes plays an essential role in inhibiting the nociceptive process. The molecules identified as their inhibitors in this project may represent new therapeutic agents useful in the treatment of chronic pain.
DURATION OF PROJECT
PHASE 1
PHASE 2
PHASE 2
01/09/2020-31/12/2020
Structure-activity analysis
PHASE 2
PHASE 2
PHASE 2
01/01/2021- 31/12/2021
Development of a computational drug repurposing algorithm for the identification of key structures, with affinity for the endogenous enzymes responsible for the degradation of endocannabinoids and representing therapeutic solutions for the management of chronic pain
PHASE 3
PHASE 2
PHASE 3
01/01/2022-31/08/2022
"In vivo" validation of "in silico"/"in vitro" studies